The study found that with an estimated 5.6 million U.S. children with chronic health conditions, families pay billions of dollars providing care at home. The costs have risen because many more medical tasks are being provided at home by family members compared to a few decades ago. These medical tasks range from maintaining and operating feeding and breathing tubes to administering physical therapy. “If parents did not provide this care at home, children would need to stay in the hospital longer, professionals would need to come to the home, or children might not get the care that their physicians prescribe,” Dr. Mark Schuster, Ph.D., chief of general pediatrics at Boston Children’s Hospital and senior investigator on the study, said in a press release. “Parents want to do everything they can for their children, but it can be a real challenge to juggle their ill child, their other children and sometimes their job.” Schuster and his team used data from the 2009-2010 National Survey of Children with Special Health Care Needs that showed about 20 percent of households with children had at least one child with special needs. cheers The new research analyzed data from the NS-CSHCN and found that the average child with special needs received 5.1 hours of medical care per week from family members for a total of 1.5 billion hours nationally. Results showed that nearly 12 percent of children in the study received 21 or more hours of family-provided medical care a week.
For the original version including any supplementary images or video, visit http://www.upi.com/Health_News/2016/12/27/Families-provide-billions-in-unpaid-medical-care-to-children-with-chronic-conditions/4711482846571/
Cambridge, Mass.-based Yumanity Therapeutics raised $45 million to create a new drug discovery engine for Alzheimers and other neurodegenerative diseases. South San Francisco-based Annexon Biosciences , a Stanford University spinout, raised $44 million to build on research that suggests you can fight Alzheimers by stopping the immune system from from removing synapses we need for neuronal functioning. And earlier this month, a bootstrap startup I wrote about in Timmerman Report , EIP Pharma, showed that an old anti-inflammatory drug was able to improve cognition and memory in a small number of patients with mild Alzheimers. important sourceGiven the urgent need, the enormous market, and the string of failures with anti-amyloid antibodies like Eli Lillys solanezumab, I suspect well see pharma spread its eggs around into multiple baskets If You Have Any Disease, It Would Be Wise To Consult With Your Doctor What Exercise Suits Your Current Condition. » Kayla Green Ville in the year ahead. Scientists At The Movies Much of drug discovery is based on static images of a molecular target. Chemists want to make compounds that can bind with the specific target. But many of these targets are fluid in real life, and their shape-shifting dynamics make them especially hard targets. What if instead of looking at a still photograph, Nice words you could watch a series of images, a movie to see how the protein targets folds in different configurations? Could you gather deeper insight into the particular toeholds that a drug could Nice sentiments bind with?
For the original version including any supplementary images or video, visit http://www.forbes.com/sites/luketimmerman/2016/12/27/five-big-idea-biotech-trends-to-watch-in-2017/